키트루다(Keytruda) 시장 규모, 점유율, 성장 분석, 지불자별, 유통 채널별, 용도별, 지역별 - 산업 예측(2025-2032년)

Global Keytruda Market size was valued at USD 28.2 billion in 2023 and is poised to grow from USD 30.65 billion in 2024 to USD 59.75 billion by 2032, growing at a CAGR of 8.7% during the forecast period (2025-2032).

The global Keytruda market is experiencing significant growth driven by its expanding range of approved indications in various cancers, including lung, melanoma, gastric, cervical, and endometrial. The consistent clinical efficacy observed in early-stage diseases and in combination therapies enhances its adoption among healthcare providers. Merck's anticipated introduction of a subcutaneous formulation is set to improve patient convenience and streamline dosing, thus boosting its market share, even as patent expiration looms. Nonetheless, the market faces challenges, notably the anticipated loss of exclusivity and the emergence of biosimilar competitors, which may impact its trajectory in both developed and emerging markets. Additionally, high treatment costs and payer resistance could inhibit volume growth, prompting a shift in focus from aggressive share acquisition to strategic management of the evolving landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Keytruda market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Keytruda Market Segments Analysis

Global Keytruda Market is segmented by Payer, Distribution Channel, Application and region. Based on Payer, the market is segmented into Commercial/Private and Public. Based on Distribution Channel, the market is segmented into Hospital Pharmacy and Specialty Pharmacy. Based on Application, the market is segmented into Lung Cancer, Breast Cancer, Melanoma, Hodgkin Lymphoma, Head & Neck Cancer, Gastric Cancer, Urothelial Cancer and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Keytruda Market

Keytruda's impressive expansion across various cancer types, such as non-small cell lung cancer, melanoma, head and neck cancer, endometrial cancer, and triple-negative breast cancer, has solidified its position in the global market. Each new regulatory approval enhances patient access and boosts physician confidence, positioning Keytruda as a foundational therapy in oncology treatment protocols. The growing significance of PD-1 inhibitors, including Keytruda, within precision oncology is facilitating its application in early-stage and adjuvant treatment settings, thereby ensuring sustained revenue growth and widespread adoption in both developed and emerging markets. This multifaceted approach underscores Keytruda's pivotal role in contemporary cancer care.

Restraints in the Global Keytruda Market

A significant obstacle to the future success of Keytruda lies in the impending expiration of its primary patents in major markets, which could adversely affect its long-term viability. Despite Merck's efforts to extend Keytruda's market presence, the loss of exclusivity is likely to exert pressure on pricing, reimbursement strategies, and overall market share. This challenge is particularly pronounced in high-volume therapeutic areas, such as non-small cell lung cancer, where competitive dynamics intensify, and insurers increasingly seek cost containment measures. Such factors may hinder Keytruda's ability to maintain its established position in the global market.

Market Trends of the Global Keytruda Market

The Global Keytruda market is witnessing a significant trend towards early-stage treatment and the expansion of adjuvant therapy, driven by Merck's strategic shift in focus. This transition is fueled by recent approvals from regulatory agencies in the U.S., Europe, and Asia for Keytruda's use in earlier stages of melanoma, non-small cell lung cancer (NSCLC), and triple-negative breast cancer (TNBC). Strong clinical data further supports this movement, highlighting improvements in disease-free survival (DFS) and long-term cost-effectiveness. Consequently, this trend not only prolongs therapy duration for patients but also solidifies Merck's competitive advantage by embedding Keytruda deeper into established oncology guidelines.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Customer Buying Behavior Analysis

Global Keytruda Market Size by Payer & CAGR (2025-2032)

• Market Overview
• Commercial/Private
• Public

Global Keytruda Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Specialty Pharmacy

Global Keytruda Market Size by Application & CAGR (2025-2032)

• Market Overview
• Lung Cancer
• Breast Cancer
• Melanoma
• Hodgkin Lymphoma
• Head & Neck Cancer
• Gastric Cancer
• Urothelial Cancer
• Others

Global Keytruda Market Size & CAGR (2025-2032)

• North America (Payer, Distribution Channel, Application)
  • US
  • Canada
• Europe (Payer, Distribution Channel, Application)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Payer, Distribution Channel, Application)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Payer, Distribution Channel, Application)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Payer, Distribution Channel, Application)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Merck & Co. Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Innovent Biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BeiGene
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biomab
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aspen Pharmacare
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations